AMS Visits Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University
Photo 1: Siriraj Hospital, Faculty of Medicine, Mahidol University, Bangkok, Thailand
BANGKOK, Thailand —AMS, a Tokyo-based startup originating from Hokkaido University, today announced a visit to the Department of Radiology at Siriraj Hospital, Faculty of Medicine, Mahidol University. During the visit, AMS introduced its proprietary BSX active urine processing system and conducted a preliminary adsorption experiment using Iodine-131 (I-131).
Photo 2: AMS CEO Sugawara presenting the BSX system to faculty and staff of the Department of Radiology
The BSX system is designed to address a critical global challenge in nuclear medicine — the management of radioactive urine generated by patients undergoing targeted radionuclide therapy (TRT). By actively adsorbing radionuclides from patient urine through a proprietary column technology, the BSX system significantly reduces the radioactivity of processed urine, enabling hospitals to expand patient capacity without costly infrastructure additions.
Photo 3: AMS Demonstration Device used for the I-131 adsorption experiment at the hospital laboratory
The I-131 adsorption experiment conducted at Siriraj Hospital was designed to explore the system's applicability beyond its initial indication. The results of this preliminary experiment will inform ongoing research and development efforts as AMS continues to expand the BSX platform to support a broader range of radioactive therapeutic drugs.
Photo 4: AMS team demonstrating the adsorption column to radiologists and medical staff
Siriraj Hospital is one of Thailand’s leading academic medical centers and a prominent regional hub for nuclear medicine. During the visit, AMS had the opportunity to meet with Associate Professor Shuichi Shiratori of the Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, whose expertise provided valuable insights for future collaboration. This visit marks an important step in AMS’s international expansion strategy across Southeast Asia.
"The treatment of radioactive pharmaceutical wastewater is a global challenge. We are committed to bringing the BSX system to leading nuclear medicine centers worldwide, and Siriraj Hospital represents exactly the kind of forward-thinking institution we seek to partner with." — Yuichiro Sugawara, President & CEO, AMS
About Advanced Medical Science-Planning Inc. (AMS)
AMS is a Tokyo-based startup originating from Hokkaido University, focused on solving critical infrastructure challenges in nuclear medicine. The company's flagship BSX system processes patient urine containing radioactive substances, adsorbing over 99% of radionuclides and enabling hospitals to treat more patients without expanding tank storage. The BSX system is currently in use at leading institutions in Japan and is being actively introduced internationally.
Media Contact
Advanced Medical Science-Planning Inc.
Email: info@ams-plan.com
Website:www.ams-plan.com.